Initiate three Phase 2 clinical trials for RP2/3
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 7 Dec 2022
- Due
- 30 Jun 2023
- Checked
- 1 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Three Phase 2 clinical trials are to be conducted with RP2/3, each initiating in the first half of 2023.”
What we found
Evidence strength A What the grades mean
The company failed to initiate all three planned Phase 2 trials for RP2/3 by the first half of 2023, with some trials delayed to the third quarter of 2023.
-
A Replimune Group, Inc. 8-K filed 2023-08-03
“RP2 and RP3 Phase 2 programs; third-line colorectal cancer clinical trial initated, first- and second-line hepatocellular carcinoma trials expected to initiate this quarter” ✓ confirmed on the page
Market reaction: the shares moved -11.2% against the S&P 500 over the three sessions around the disclosure (2 Aug 2023 to 7 Aug 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 7 Dec 2022
Deadline 30 Jun 2023 (“in the first half of 2023”) · target 3 trials
-
Version 2 · stated 9 Feb 2023
Deadline 30 Jun 2023 (“mid-year”) · wording expected
“These Phase 2 clinical trials are expected to initiate around mid-year.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Three Phase 2 clinical trials for RP2/3
- Target
- 3 trials
- In the company’s control
- High
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Partly met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-REPL-002699 · Corrections policy